NYSE American's $0.25 Rule vs. Nasdaq's $5M Review
Two US exchanges are tightening their continued listing standards. The timelines, mechanics, and current legal status of each rule differ significantly. Here is what listed companies need to know.
Overview: What Connects These Two Rules
Two US stock exchanges are tightening their continued listing standards in 2026. The mechanics, the timelines, and the current legal status of each rule are different enough that they require separate treatment. What connects them is a shared concern: low-priced and low-market-value securities carry risks for investors and market integrity that the exchanges believe existing rules no longer adequately address.
For public companies listed on NYSE American or Nasdaq, particularly smaller issuers and micro-cap companies, the compliance implications of each rule are material. The preparation window for one of them is already running.
July 1, 2027
NYSE American $0.25 rule effective date
$0.25
Single-day close below this triggers immediate trading suspension on NYSE American
$5M
Nasdaq proposed minimum Market Value of Listed Securities
Stayed
Nasdaq $5M MVLS rule: not enforceable pending full SEC review
NYSE American: The $0.25 Hard Floor
On August 14, 2026, the SEC approved amendments to the NYSE American Company Guide establishing a new $0.25 minimum trading price requirement for listed securities. The rule takes effect July 1, 2027.
THE SINGLE-DAY TRIGGER
If a listed security closes below $0.25 on any single trading day, NYSE American will immediately suspend trading in that security and commence delisting proceedings. There is no 30-day average. There is no number-of-consecutive-days threshold. One closing price below $0.25 is enough.
Why the Prior Rule Was Not Enough
Before this amendment, NYSE American’s practice was to engage with issuers whose securities traded below $1.00 per share and to initiate suspension and delisting proceedings if a security traded below $0.10 per share. That $0.10 threshold was policy-based rather than formally codified. The amended rule replaces it with an express $0.25 requirement that carries immediate consequences.
NYSE American also retains discretion above the $0.25 threshold. The amended rule expressly confirms the exchange’s authority to suspend trading or delist a security that has experienced a rapid decline and reached an abnormally low level from which, in the exchange’s view, it is unlikely to recover, even if that security has not closed below $0.25. No objective numerical standards govern that discretion.
No Cure Period. No Compliance Plan.
Under NYSE American’s standard Section 1009 compliance procedures, a company that falls out of compliance with a listing standard typically receives a notification, a cure period, and an opportunity to submit a compliance plan. None of those apply to the $0.25 rule. Once the threshold is breached, trading stops. The issuer retains the right to appeal, but the trading suspension remains in effect during that appeal.
The Reverse Stock Split Problem
The nine-month implementation period before July 1, 2027 was specifically designed to give affected issuers time to seek stockholder approval for a reverse stock split. NYSE American and the SEC noted that the extended timeline would allow issuers to bring the matter to their 2027 annual meetings.
However, reverse stock splits are a limited tool under NYSE American’s rules. Two restrictions apply:
- The 200-to-1 cumulative ceiling. Section 1003(f)(vi) provides that NYSE American will immediately commence suspension and delisting proceedings if an issuer has effected one or more reverse stock splits in the preceding two-year period with a cumulative ratio of 200-to-1 or greater. That issuer is not eligible for a cure period.
- Other listing standard compliance. Section 1003(f)(vii) adds that a reverse stock split causing an issuer to fall below any other continued listing standard triggers the same immediate proceedings.
WHAT COMPANIES NEED TO DO BEFORE JULY 1, 2027
Review prior split history and calculate whether a proposed ratio would hit the 200-to-1 cumulative ceiling.
Verify that the resulting share count satisfies all other NYSE American listing standards.
Check the impact on outstanding warrants, convertible securities, equity awards, and financing arrangements.
Establish internal monitoring for when the trading price approaches $0.25.
Consider appropriate disclosure in upcoming periodic reports and proxy statements regarding the new minimum price requirement.
Nasdaq: The $5M MVLS Rule Under Full SEC Review
On July 22, 2026, the SEC initially approved a Nasdaq rule that would require companies listed on the Nasdaq Global Select Market, the Nasdaq Global Market, and the Nasdaq Capital Market to maintain a minimum Market Value of Listed Securities of at least $5 million. Companies falling below that threshold for 30 consecutive business days would be immediately subject to suspension and delisting, with no cure period and no compliance plan opportunity.
CURRENT STATUS: STAYED AND UNENFORCEABLE
Shortly after the initial approval, the SEC issued a stay. On September 11, 2026, the SEC formally granted petitions for a full review of the proposal. The rule is currently stayed and cannot be enforced. The public comment period closed October 6, 2026. The review is expected to take several months.
What the SEC Is Weighing
The SEC’s full review will require it to balance two competing interests, as outlined in the review order:
- Nasdaq’s stated goal: protecting investors from manipulation and market disorder associated with low-priced stocks.
- Industry concerns: ensuring the rigid standard does not disproportionately harm micro-cap and emerging growth companies by cutting off access to public capital that is necessary to sustain operations and pursue strategic growth.
The SEC’s decision to grant full review does not predetermine the outcome. It means the proposal will receive closer scrutiny before it can be enforced. Any outcome is possible: the rule may be adopted in its current form, modified, or rejected.
The stayed status of the $5M MVLS rule does not mean smaller Nasdaq issuers can stop monitoring their market value. The relevant response options need to be ready before a deficiency occurs, not after.
The Two Rules Side by Side
| 🟢 NYSE American $0.25 Rule | 🟡 Nasdaq $5M MVLS Rule |
Exchange | NYSE American | Nasdaq |
Rule | $0.25 minimum trading price (Section 1003(f)(v)) | $5M minimum Market Value of Listed Securities (MVLS) |
Approved by SEC | August 14, 2026 | July 22, 2026 (initially) |
Current status | Approved. Effective July 1, 2027 | Stayed. Under full SEC review. |
Trigger | Single trading day close below $0.25 | MVLS below $5M for 30 consecutive business days |
Cure period | None | None (as proposed) |
Appeal rights | Retained. Trading suspension remains during appeal. | To be determined pending outcome of SEC review. |
Current enforceability | Yes, from July 1, 2027 | No. Rule is stayed. |
Prior threshold | $0.10 (policy-based, not codified) | No prior MVLS minimum |
Both rules share a structural feature that distinguishes them from standard listing deficiency processes: they eliminate the cure period that issuers normally receive when they fall out of compliance. NYSE American’s $0.25 rule eliminates it entirely. Nasdaq’s proposed $5M MVLS rule would do the same.
That design reflects a deliberate policy choice. Both exchanges concluded that the deficiency categories these rules address represent conditions serious enough that the standard compliance plan process is inadequate. For issuers, the practical implication is the same in both cases: the time to act is before the threshold is breached, not after.
What This Means for SEC Filers
Both rules affect companies with existing SEC reporting obligations. A trading suspension or delisting does not end those obligations. A company suspended from trading on NYSE American or delisted from Nasdaq remains subject to Exchange Act reporting requirements as long as it has more than 300 shareholders of record, until it formally deregisters.
The delisting itself may also trigger disclosure obligations. A trading suspension or commencement of delisting proceedings is a material event that typically requires prompt disclosure on Form 8-K. Companies with active shelf registration statements or pending capital raises will face additional complications.
THE DUAL COMPLIANCE RISK
A company under exchange scrutiny for a potential listing deficiency that also has EDGAR filing errors, iXBRL tagging issues, or delayed Form 10-Qs is managing two compliance problems simultaneously. Clean, accurate, and timely SEC filings matter most precisely when a company can least afford additional regulatory friction.
DataTracks prepares and files Form 10-K, Form 10-Q, Form 8-K, and Section 16 reports in iXBRL and XML formats with EDGAR-direct submission and DQC validation, supporting accurate and timely filings for companies navigating a high-scrutiny period. Section 16 filing services are available separately for insiders managing ownership reporting obligations during a period of exchange compliance review.
KEY TAKEAWAYS
✓ NYSE American’s $0.25 minimum trading price rule was approved by the SEC on August 14, 2026, and takes effect July 1, 2027.
✓ A single trading day close below $0.25 triggers immediate suspension and delisting proceedings on NYSE American. There is no cure period and no compliance plan opportunity.
✓ NYSE American retains discretion to act above $0.25 for securities experiencing a precipitous decline.
✓ Reverse stock splits are a limited tool: the 200-to-1 cumulative ratio ceiling and other listing standard constraints significantly reduce available options for companies that have already completed prior splits.
✓ Nasdaq’s $5M MVLS rule was initially approved July 22, 2026, then stayed. On September 11, the SEC granted full review. The rule is currently unenforceable.
✓ The comment period for the Nasdaq $5M MVLS review closed October 6, 2026. The SEC’s decision could take several months.
✓ Companies under exchange scrutiny should ensure their SEC filings are accurate and timely. A listing deficiency and an EDGAR compliance issue at the same time compounds the risk.
Filing accurately during a high-scrutiny period matters.
Companies under exchange scrutiny managing a delisting risk cannot afford EDGAR filing errors or iXBRL tagging issues at the same time. DataTracks prepares and files Form 10-K, Form 10-Q, Form 8-K, and Section 16 reports in iXBRL and XML formats with EDGAR-direct submission and DQC validation.
